134 related articles for article (PubMed ID: 36567618)
1. Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study.
El Desoky ES; Taha AF; Mousa HS; Ibrahim A; Saleh MA; Abdelrady MA; Hareedy MS
J Oncol Pharm Pract; 2023 Oct; 29(7):1673-1686. PubMed ID: 36567618
[TBL] [Abstract][Full Text] [Related]
2. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
3. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.
Braal CL; Westenberg JD; Buijs SM; Abrams S; Mulder TAM; van Schaik RHN; Koolen SLW; Jager A; Mathijssen RHJ
Breast Cancer Res Treat; 2022 Aug; 195(1):65-74. PubMed ID: 35842520
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
7. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale.
Agema BC; Buijs SM; Sassen SDT; Mürdter TE; Schwab M; Koch BCP; Jager A; van Schaik RHN; Mathijssen RHJ; Koolen SLW
Biomed Pharmacother; 2023 Apr; 160():114369. PubMed ID: 36753957
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.
Braal CL; Jager A; Hoop EO; Westenberg JD; Lommen KMWT; de Bruijn P; Vastbinder MB; van Rossum-Schornagel QC; Thijs-Visser MF; van Alphen RJ; Struik LEM; Zuetenhorst HJM; Mathijssen RHJ; Koolen SLW
Clin Pharmacokinet; 2022 Apr; 61(4):527-537. PubMed ID: 34786650
[TBL] [Abstract][Full Text] [Related]
9. Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.
de Krou S; Rosing H; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2017 Apr; 39(2):132-137. PubMed ID: 28045782
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
[TBL] [Abstract][Full Text] [Related]
11. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
Sanchez-Spitman AB; Moes DAR; Swen JJ; Dezentjé VO; Lambrechts D; Neven P; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1141-1152. PubMed ID: 32468081
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
15. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
16. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
17. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
19. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
20. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]